依达拉奉清除自由基机制及临床应用

摘要/Abstract

摘要： 研究证实,多种人类疾病的发生与机体过量自由基的产生相关,过量自由基损伤脂质,蛋白质和DNA等生物大分子,导致对机体的有害作用。依达拉奉(edaravone)为强效自由基清除剂,于2001年在日本上市,临床上主要用于治疗急性缺血性脑中风。本文对依达拉奉清除自由基的机制和治疗多种人类疾病的研究进展作简要概述,主要介绍了依达拉奉在治疗脑、心脏等多器官的缺血/再灌注损伤,肌萎缩侧索硬化症(ALS)、帕金森病(PD)、阿尔茨海默病(AD)、多发性硬化症等神经性疾病,癫痫,动脉粥样硬化,肝、肺纤维化病变,类风湿性关节炎和突发性耳聋等多种人类疾病中的应用,为进一步开发依达拉奉在临床上的新用途提供参考。

关键词: 依达拉奉, 自由基, 氧化应激

Abstract: Researches certified that overproduction of free radicals has been implicated in many human diseases , as excessive free radicals damage biomacromole- cules such as lipids ,protein and DNA , leading to deleterious effect of the body. Edaravone, a potent free radical scavenger, has been approved in Japan for the treatment of acute cerebral infarction since April 2001. This review illustrated the hypothetical free radical-scavenging mechanism of edaravone and summarized the research progress of edaravone in treating many human diseases. The protective effect of edaravone in treating ischemic/reperfusion injury in many organs( brain, heart et al), neurodegenerative diseases(Amyotrophic Lateral Sclerosis, Parkinson's disease, Alzheimer's disease et al), epilepsy, atherosclerosis, hepatic fibrosis and pulmonary fibrosis diseases, rheumatoid arthritis and sudden hearing loss are described in this review, which may provide reference for the novel clinical application of edaravone in future.

Key words: Edaravone, Free radical, Oxidant stress

中图分类号:

R969

马利萍, 孙建国, 彭英, 王广基. 依达拉奉清除自由基机制及临床应用[J]. 中国临床药理学与治疗学, 2011, 16(3): 341-348.

MA Li-ping, SUN Jian-guo, PENG Ying, WANG Guang-ji. Free radical scavenging mechanism of edaravone and its clinical application[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(3): 341-348.

参考文献

[1] Chan PH. Reactive oxygen radicals in signaling and damage in the ischemic brain[J]. J Cereb Blood Flow Metab, 2001, 21 (1):2-14.
[2] Watanabe T,Tahara M, Todo S. The novel antioxidant edaravone: from bench to bedside[J]. Cardiovasc Ther, 2008, 26 (2):101-114.
[3] Sano H,Kamijo T,Ino T, et al. Edaravone, a free radical scavenger, in the treatment of idiopathic sudden sensorineural hearing loss with profound hearing loss[J]. Auris Nasus Larynx, 2010, 37 (1):42-46.
[4] Watanabe T,Tanaka M,Watanabe K,et al. [Research and development of the free radical scavenger edaravone as a neuroprotectant] [J]. Yakugaku Zasshi, 2004, 124 (3):99-111.
[5] Zhang N,Komine-Kobayashi M,Tanaka R, et al. Edaravone reduces early accumulation of oxidative products and sequential inflammatory responses after transient focal ischemia in mice brain[J]. Stroke, 2005, 36 (10):2220-2225.
[6] Amemiya S,Kamiya T,Nito C,et al. Anti-apoptotic and neuroprotective effects of edaravone following transient focal ischemia in rats[J]. Eur J Pharmacol, 2005, 516 (2):125-130.
[7] Otomo E. Effect of a novel free radical scavenger, edaravone (MCI-186), on acute brain infarction. Randomized, placebo-controlled, double-blind study at multicenters[J]. Cerebrovasc Dis, 2003, 15 (3):222-229.
[8] Shichinohe H,Kuroda S,Yasuda H, et al. Neuroprotective effects of the free radical scavenger Edaravone (MCI-186) in mice permanent focal brain ischemia[J]. Brain Res, 2004, 1029 (2):200-206.
[9] 李勇,孔令青,高洪,等. 自由基与疾病研究进展[J]. 动物医学进展, 2008, 29 (4):85-88.
[10] Valko M,Leibfritz D,Moncol J, et al. Free radicals and antioxidants in normal physiological functions and human disease[J]. Int J Biochem Cell Biol, 2007, 39 (1):44-84.
[11] Lin M,Katsumura Y,Hata K, et al. Pulse radiolysis study on free radical scavenger edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one)[J]. J Photochem Photobiol B, 2007, 89 (1):36-43.
[12] Abe S,Kirima K,Tsuchiya K,et al. The reaction rate of edaravone (3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186)) with hydroxyl radical[J]. Chem Pharm Bull (Tokyo), 2004, 52 (2):186-191.
[13] Abe K,Yuki S,Kogure K. Strong attenuation of ischemic and postischemic brain edema in rats by a novel free radical scavenger[J]. Stroke, 1988, 19 (4):480-485.
[14] Nishi H,Watanabe T,Sakurai H,et al. Effect of MCI-186 on brain edema in rats[J]. Stroke, 1989, 20 (9):1236-1240.
[15] Watanabe T,Yuki S,Egawa M, et al. Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions[J]. J Pharmacol Exp Ther, 1994, 268 (3):1597-1604.
[16] Lapchak PA. A critical assessment of edaravone acute ischemic stroke efficacy trials: is edaravone an effective neuroprotective therapy [J] ? Expert Opin Pharmacother, 2010, 11 (10):1753-1763.
[17] 黄建敏,杜书章,张晓坚. 依达拉奉在体外循环心脏手术患者中治疗心肌缺血再灌注损伤作用的 Meta 分析[J]. 药学与临床研究, 2010, 18 (6):554-557.
[18] Tsujita K,Shimomura H,Kaikita K, et al. Long-term efficacy of edaravone in patients with acute myocardial infarction[J]. Circ J, 2006, 70 (7):832-837.
[19] Nakamura Y,Yamada Y,Shimomura H,et al. Effect of edaravone on plasma monocyte chemoattractant protein-1 levels in patients with acute myocardial infarction[J]. J Cardiol, 2009, 54 (3):416-424.
[20] Tsujita K,Shimomura H,Kawano H,et al. Effects of edaravone on reperfusion injury in patients with acute myocardial infarction[J]. Am J Cardiol, 2004, 94 (4):481-484.
[21] Matsumoto S,Hanai T,Shimizu N, et al. Effect of edaravone on ischemia/reperfusion injury in rat urinary bladder--changes in smooth muscle cell phenotype and contractile function[J]. Aktuelle Urol, 2010, 41 Suppl 1:S46-49.
[22] Tamamura M,Saito M,Kinoshita Y, et al. Protective effect of edaravone, a free-radical scavenger, on ischaemia-reperfusion injury in the rat testis[J]. BJU Int, 2010, 105 (6):870-876.
[23] Song Y,Gong YY,Xie ZG,et al. Edaravone (MCI-186), a free radical scavenger, attenuates retinal ischemia/reperfusion injury in rats[J]. Acta Pharmacol Sin, 2008, 29 (7):823-828.
[24] Kaur C,Ling EA. Antioxidants and neuroprotection in the adult and developing central nervous system[J]. Curr Med Chem, 2008, 15 (29):3068-3080.
[25] Pan YH, Wang YC, Zhang LM, et al. Protective effect of edaravone against PrP106-126-induced PC12 cell death[J]. J Biochem Mol Toxicol, 2010, 24 (4):235-241.
[26] Barber SC, Mead RJ,Shaw PJ. Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target[J]. Biochim Biophys Acta, 2006, 1762 (11/12):1051-1067.
[27] Ito H,Wate R,Zhang J, et al. Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice[J]. Exp Neurol, 2008, 213 (2):448-455.
[28] Takahashi R. Edaravone in ALS[J]. Exp Neurol, 2009, 217 (2):235-236.
[29] Yoshino H,Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (Phase II study)[J]. Amyotroph Lateral Scler, 2006, 7 (4):241-245.
[30] Yuan WJ,Yasuhara T,Shingo T,et al. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons[J]. BMC Neurosci, 2008, 9:75.
[31] Kawasaki T,Ishihara K,Ago Y, et al. Edaravone (3-methyl-1-phenyl-2-pyrazo- lin-5-one), a radical scavenger, prevents 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-indu- ced neurotoxicity in the substantia nigra but not the striatum[J]. J Pharmacol Exp Ther, 2007, 322 (1):274-281.
[32] 陈应柱,刘刚,杨德刚,等. 依达拉奉治疗帕金森病的疗效观察[J]. 临床神经病学杂志, 2009, 22 (5):384-386.
[33] 王冰. 依达拉奉治疗血管性帕金森综合征的疗效观察[J]. 中国实用神经疾病杂志,2007, 10 (9):45-46.
[34] 马烈,孙斌. 依达拉奉治疗血管源性帕金森综合征的疗效观察[J]. 中国全科医学, 2008, 11 (10A):1794-1795.
[35] 黄艳,董志. 氧化应激和阿尔茨海默病[J]. 中国临床药理学与治疗学, 2005, 10 (5):485-488.
[36] 于明,包晓群. 依达拉奉对 Aβ25-35诱导分化 PC12细胞 NF-κB p65基因表达的影响[J]. 中国老年学杂志, 2008, 28 (22):2199-2201.
[37] 王鹏军,宋荣蓉,赫丹丹. PI3K/Akt信号在阿尔茨海默病样细胞中的作用及依达拉奉对其影响[J]. 中风与神经疾病杂志, 2010, 27 (1):12-15.
[38] Moriya M,Nakatsuji Y,Miyamoto K,et al. Edaravone, a free radical scavenger, ameliorates experimental autoimmune encephalomyelitis[J]. Neurosci Lett, 2008, 440 (3):323-326.
[39] 张巧莲,郭力,胡岩芳,等. Nrf2和HO-1在实验性自身免疫性脑脊髓炎大鼠脊髓中的动态表达及依达拉奉保护机制的研究[J]. 中国免疫学杂志, 2010, 26 (6):514-519.
[40] Kamida T,Fujiki M,Ooba H,et al. Neuroprotective effects of edaravone, a free radical scavenger, on the rat hippocampus after pilocarpine-induced status epilepticus[J]. Seizure, 2009, 18 (1):71-75.
[41] Wang HP,Li GQ. Protection of edaravone on neurons and its effects on the expression of interleukin-lbeta in juvenile rat hippocampus following status convulsion[J]. Zhongguo Dang Dai Er Ke Za Zhi, 2010, 12 (3):205-210.
[42] Miyamoto R,Shimakawa S,Suzuki S,et al. Edaravone prevents kainic acid-induced neuronal death[J]. Brain Res, 2008, 1209:85-91.
[43] 管得宁,运徐,王翀,等. 依达拉奉辅助治疗难治性癫痛的疗效及机制[J]. 中风与神经疾病杂志, 2007, 24 (3):358-359.
[44] 温玉梅,闫致旺. 依达拉奉辅助治疗全身强直-阵挛发作癫痫的疗效与机制[J]. 河北医药, 2010, 32 (17):2368-2369.
[45] Arii K,Kumon Y,Ikeda Y, et al. Edaravone inhibits the disease activity in rheumatoid arthritis[J]. J Clin Pharm Ther, 2006, 31 (2):197-199.
[46] Arii K,Kumon Y,Ikeda Y,et al. Edaravone inhibits rheumatoid synovial cell proliferation and migration[J]. Free Radic Res, 2006, 40 (2):121-125.
[47] Arii K,Kumon Y,Sugahara K,et al. Edaravone inhibits collagen-induced arthritis possibly through suppression of nuclear factor-kappa B[J]. Mol Immunol, 2008, 45 (2):463-469.
[48] Xi H,Akishita M,Nagai K,et al. Potent free radical scavenger, edaravone, suppresses oxidative stress-induced endothelial damage and early atherosclerosis[J]. Atherosclerosis, 2007, 191 (2):281-289.
[49] Radhakrishnan G, Suzuki R, Maeda H, et al. Inhibition of neointimal hyperplasia development by MCI-186 is correlated with downregulation of nuclear factor-kappaB pathway[J]. Circ J, 2008, 72 (5):800-806.
[50] Yoshida H,Sasaki K,Namiki Y, et al. Edaravone, a novel radical scavenger, inhibits oxidative modification of low-density lipoprotein (LDL) and reverses oxidized LDL-mediated reduction in the expression of endothelial nitric oxide synthase[J]. Atherosclerosis, 2005, 179 (1):97-102.
[51] Tanaka H,Ueda H,Fukuchi H,et al. Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine[J]. Clin Exp Med, 2009, 9 (3):229-233.
[52] 帅训军,宫倩红,艾登斌,等. 依达拉奉对单肺通气患者围术期细胞因子IL-6、IL-8及其mRNA表达的影响[J]. 中国临床药理学与治疗学, 2010, 15(3):326-330.
[53] Asai T,Ohno Y,Minatoguchi S,et al. The specific free radical scavenger edaravone suppresses bleomycin-induced acute pulmonary injury in rabbits[J]. Clin Exp Pharmacol Physiol, 2007, 34 (1/2):22-26.
[54] Tajima S,Soda M,Bando M, et al. Preventive effects of edaravone, a free radical scavenger, on lipopolysaccharide-induced lung injury in mice[J]. Respirology, 2008, 13 (5):646-653.
[55] Zhi Q,Sun H,Qian X,et al. Edaravone, a novel antidote against lung injury and pulmonary fibrosis induced by paraquat[J]. Int Immunopharmacol, 2011, 11 (1):96-102.
[56] 钱欣梅,张向阳. 氧自由基与耳聋[J]. 济宁医学院学报, 2003, 26 (2):82-83.